Transfusion-associated graft-versus-host disease (TA-GVHD) was described in immunodeficient children nearly three decades ago (1) . By 1980 it had been reported in recipients of bone marrow transplants, in patients with leukemia, Hodgkin's disease, and lymphoma, and in neonates. with hemolytic disease of the newborn who had received intrauterine transfusions. During the mid 1980's, the American Association of Blood Banks (AABB) stated that "it may be appropriate to irradiate blood and establish transfusion service protocols to reduce the risk of GVHD in selected immunosuppressed patients" (2) and fetuses receving intrauterine transfusions (3) . In 1986 the syndrome of post-operative erythroderma, previously reported in Japanese patients who had undergone cardiac surgery, was recognized as TA-GVHD in two immunocompetent patients who had received fresh, non-irradiated blood from random donors (4) . In 1989 Thaler reported two fatal cases in immunocompetent adult patients who had received fresh, non-irradiated blood from their children (5) . In each case the role of the HLA system in the etiology of this disease was elucidated by determining that a sibling blood donor was homozygous for one of the recipient's HLA haplotypes. The immunocompentent recipient failed to recognize and destroy donor lymphocytes, whereas functional donor lymphocytes recognized the recipient's disparate haplotype and mounted a graft-versushost response. Recognizing the potential risk of TA-GVHD from first-degree family relatives, irradiation of cellular blood products (15 Gy) was recommended by the AABB in 1991 (6) . The risk of TA-GVHD following transfusion of blood from second-degree relatives was estimated by a mathematical model to be greater than that after transfusion from siblings (7) . Accordingly, the AABB recommended that recipients of donor units from blood relatives should be irradiated with a minimum of 25 Gy (8) . The rationale for this decision is supported by a recent report of fatal TA-GVHD following transfusion of blood from a seconddegree relative (9) .
In the United States, irradiation of cellular blood products is recommended for recipients of bone marrow transplants, selected immunoincompentent and immunocompromised recipients, fetuses receiving intrauterine transfusions, and (most recently) recipients of directed blood donations from blood relatives. Although gamma irradiation is the universally accepted method for preventing TA-GVHD, delineating the patients at risk who require irradiated blood products has been difficult. This arises because of our inability to define the degree of immunosuppression and to recognize the presence of other factors that may predispose to this disease. In Japan the high incidence of TA-GVHD appears to be related to the frequent use of family members as blood donors, the genetic homogeneity of the Japanese, and the use of fresh (less than 3 days old) blood. However, other factors, such as the minimal dose of lymphocytes required to induce TA-GVHD, the role of antigen presenting cells, the role of minor histocompatibility antigens, and the infuence of cytokines remain to be elucidated.
In a recent review by Greenbaum (10), 51 of 131 (39%) cases of TA-GVHD reported in the literature were associated with hematologic malignancies, acute leukemia, Hodgkin's disease and lymphoma. The 1989-1990 AABB irradiation practice survey, representing the results of 1,327 responding institutions, revealed 18 of 42 (42%) cases of TA-GVHD occurred in patients with hematologic malignancies (11) . In addition, an irradiation practice survey of 100 pediatric and adult hematologists, oncologists and bone marrow transplant physicians revealed 14 of 39 (36%) cases of TA-GVHD were associated with hematologic malignancies (10) . Although the combination of radiation and chemotherapy was formerly considered necessary for the development of TA-GVHD in Hodgkin's dis-ease, several cases have been documented in patients who received chemotherapy alone. One wonders, therefore, why patients with Iymphoproliferative diseases and leukemia have not been designated to receive irradiated blood products, since current AABB recommendations are based on retrospective data derived empirically from comlication of case reports and from a mathematical model for second-degree relatives.
Growing awareness of this devastating though infrequent complication of transfusion has caused an increasing demand by physicians for irradiated blood products. In some hospitals these demands have been translated into irradiation policies that define patient populations by disease, by a laboratory value (absolute lymphocyte count), by ordering physician, or by clinical service. In addition to the patient groups recommended by the AABB, some hospitals have customized irradiation policies to include infants less than 4 months old, patients with acquired immune deficiency syndrome (AIDS), Hodgkin's disease, non-Hodgkin's lymphoma, and other hematologic malignancies; solid organ transplant; patients registered to "Dr. John Doe", patients admitted to a particular floor, and even patients with a predetermined absolute lymphocyte count.
Many hospitals have instituted combinations of laboratory value-dependent, diagnosis-dependent, physician-dependent and floor-dependent irradiation policies. Although most transfusion services maintain manual or computer records of patients requiring product modification (i.e.: irradiation), the failure to provide irradiated products to newly admitted or undiagnosed patients is a major shortcoming of diagnosis-dependent policies. Irradiation policies based on fluctuating laboratory values are confusing and cause inconsistent irradiation practices. The cost of irradiation, especially for patients at no defined risk of TA-GVHD, is the major problem with physiciandependent and clinical floor/service-dependent irradiation policies. Some clinicians advocate universal irradiation of cellular blood products to avoid TA-GVHD, failing to recognize the adverse consequences of postirradiation storage, the possible loss of blood inventory due to the Federal Drug Administration's (FDA) proposed 28 day postirradiation shelflife, and the cost to the patients.
Directed blood donations is a controversial transtu-2 sion practice in the USA stemming primarily from the risk of transmitting infectious disease. However, many physicians are cognizant that blood from all family members is irradiated and therefore affords recipients of these donations protection from TA-GVHD. To eliminate potential errors in identification or labeling of units from a blood relative, some transfusion services have established a uniform policy for irradiating all directed donations. This practice may encourage the use of direct donations from family and non-family donors merely to avoid TA-GVHD. Defensive medicine has further increased physician demands for irradiated blood products, fostered by the pervasive social attitude that "someone must pay for untoward effects of medical intervention/therapy", the absence of capitation limits to malpractice suits, and the legal contingency fee system in the USA. Also, the legal implications of "standard of care" pertaining to TA-GVHD remain undefined. Are physicians exempt from legal responsibility as long as they conform to the minimal standard of practice as recommended by the AABB? Or are they held accountable to a higher standard -a local, regional, national, or international standard? Furthermore, must "informed consent" include the disclosure of TA-GVHD as a remote, but severe, complication of transfusion? Does physician documentation of disclosure of the risk provide legal protection from suits relating to TA-GVHD? Since irradiation can effectively prevent this untoward consequence of transfusion, should patients have the choice of receiving irradiated products? Should patients also be informed of the unknown risk of possible mutagenesis of irradiated cells?
Cost and availability of irradiation services are major considerations for hospitals and transfusion services facing increasing physician demands. At an estimated cost of $80,000 to $100,000, it is not surprising that, as reported in the AABB transfusion practice survey, only 178 (12%) of 1444 institutional members have on-site irradiation faicilites. The use of conventional cobalt-50 source or linear accelerators in radiation therapy departments is often fraught with logistic problems such as availability of personnel at night or on weekends, sandwiching blood between patients, time delays, and cost. This has prompted many small and medium-sized hospitals to rely on blood collection centers and other blood banks or transfusion services to meet their irradiation needs. Consequently, transfusion service internal irradiation policies have been customized to address unique operational considerations. Routine and emergency irradiation requests can be accommodated with existing personnel at nominal cost in facilities equipped with on-site irradiators. In some hospitals, a priority status is given to previously irradiated units that are returned to inventory. With good product management, it is unusual for units to exceed a five day postirradiation shelflife. However, in hospitals without onsite irradiators, irradiated products may not be available on an emergency basis, delays are often encountered with routine requests, and outdate of irradiated units increases.
Whole blood, red blood cell concentrates, platelets, granulocytes and fresh plasma have all been implicated in TA-GVHD. However, as revealed in the AABB irradiation practice survey, nearly 20% of responding institutions report irradiation of both cellular and non-cellular blood products, despite little scientific data to support or refute the practice of irradiating non-cryoprotected frozen blood products. A standardized irradiation dose for optimal reduction of lymphocyte p~oliferative capacity versus the adverse consequences of irradiation has not been addressed. The proposed recommendation by the US Food and Drug Administration (FDA) to limit post-irradiation storage to 28 days is based on two studies of small sample size, utilizing different additive systems, different doses of irradiation, and different numbers of days of storage prior to evaluating survival (12, 13) . Is it not the responsiblity of an informed scientific community to evaluate and validate scientific data prior to the establishment of federal regulatory policies that have far-reaching implications?
Physicians and scientists must address issues pertaining to patients at risk for TA-GVHD; medical-legal issues of liability, informed consent, and standard of care; and the acquisition of scientific data to support the establishment of standardized policies, where indicated. Policy recommendations, possibly resulting from an irradiation concensus conference, should be generated by the scientific community rather than by regulatory agencies or public opinion.
